What is Nusano?
Nusano operates as a specialized physics-driven enterprise dedicated to stabilizing the supply of medical radioisotopes. In an industry historically plagued by scarcity and logistical bottlenecks, the company utilizes proprietary technology to ensure consistent access to high-quality isotopes. These materials are essential for diagnostic imaging, therapeutic treatments, and various industrial applications that require precise radioactive markers. By bridging the gap between advanced physics research and commercial-scale production, Nusano addresses a critical undersupply issue that has long hindered the healthcare and industrial sectors. Their market position is defined by a commitment to technical innovation and the creation of a resilient, domestic supply chain for materials that are vital to modern medicine and scientific research.
How much funding has Nusano raised?
Nusano has raised a total of $156M across 2 funding rounds:
Series A
$41M
Series C
$115M
Series A (2018): $41M, investors not publicly disclosed
Series C (2024): $115M led by The Wasatch Group, Verily, and S32
Key Investors in Nusano
The Wasatch Group
The Wasatch Group is a diversified investment firm with a focus on long-term value creation and strategic capital deployment across various industrial and commercial sectors.
Verily
Verily Life Sciences LLC is a U.S.-based healthcare technology company and subsidiary of Alphabet Inc., focused on improving health outcomes through data-driven research and digital health solutions.
S32
SISTEMA 32 specializes in integrated kitchens, wardrobes, and furniture, offering innovative and functional design solutions for both residential and commercial clients.
What's next for Nusano?
With the successful closure of this Series C round, Nusano is expected to prioritize the expansion of its manufacturing facilities and the optimization of its isotope production processes. The strategic backing from high-profile investors suggests a focus on long-term scalability and the integration of their technology into broader healthcare and industrial ecosystems. Future growth will likely center on increasing output to meet the rising global demand for medical isotopes, while simultaneously exploring new commercial partnerships to diversify their revenue streams. As the company transitions into this next phase of development, the focus will remain on operational excellence and the execution of its mission to provide a stable, reliable supply of critical radioisotopes to the global market.
See full Nusano company page
